Literature DB >> 19995747

Heart disease and rheumatoid arthritis: understanding the risks.

S E Gabriel1.   

Abstract

Patients with rheumatoid arthritis (RA) are at increased risk of mortality compared with the general population. Evidence suggests that this increased mortality can largely be attributed to increased cardiovascular death. In a retrospective study of an inception cohort of RA patients in Rochester, MN, the contribution of traditional and RA-specific risk factors was investigated to this increased risk of cardiovascular morbidity and mortality. Several traditional cardiovascular risk factors were found to behave differently in RA patients. In addition, their associations with cardiovascular disease are weaker in RA patients as increased inflammation associated with RA also appears to contribute substantially to the increased cardiovascular mortality. Furthermore, the impact of disease-modifying antirheumatic drugs and biologicals on cardiovascular disease in RA patients is unclear. Cardiovascular risk scores for the general population may underestimate the risk for RA patients. Together with other studies that have demonstrated similar associations between RA and cardiovascular mortality, these data suggest that optimal control of cardiovascular risk factors is important, but not sufficient in RA patients. RA-specific cardiovascular risk prediction tools are needed, as well as clinical trials to assess the impact of therapies and tight control of inflammation in RA patients on cardiovascular outcomes and mortality.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19995747      PMCID: PMC4308040          DOI: 10.1136/ard.2009.119404

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  15 in total

Review 1.  Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review.

Authors:  Yannis Alamanos; Paraskevi V Voulgari; Alexandros A Drosos
Journal:  Semin Arthritis Rheum       Date:  2006-10-11       Impact factor: 5.532

2.  Cardiovascular disease risk prediction in type 1 diabetes: accounting for the differences.

Authors:  Kristine Ruppert; Mark S Roberts; Trevor J Orchard; Janice C Zgibor
Journal:  Diabetes Res Clin Pract       Date:  2007-04-30       Impact factor: 5.602

3.  Deficiencies of cardiovascular risk prediction models for type 1 diabetes.

Authors:  Janice C Zgibor; Gretchen A Piatt; Kristine Ruppert; Trevor J Orchard; Mark S Roberts
Journal:  Diabetes Care       Date:  2006-08       Impact factor: 19.112

4.  Paradoxical effect of body mass index on survival in rheumatoid arthritis: role of comorbidity and systemic inflammation.

Authors:  Agustín Escalante; Roy W Haas; Inmaculada del Rincón
Journal:  Arch Intern Med       Date:  2005-07-25

5.  Prognostic importance of low body mass index in relation to cardiovascular mortality in rheumatoid arthritis.

Authors:  Hilal Maradit Kremers; Paulo J Nicola; Cynthia S Crowson; Karla V Ballman; Sherine E Gabriel
Journal:  Arthritis Rheum       Date:  2004-11

6.  Autoantibodies and the risk of cardiovascular events.

Authors:  Kimberly P Liang; Hilal Maradit Kremers; Cynthia S Crowson; Melissa R Snyder; Terry M Therneau; Veronique L Roger; Sherine E Gabriel
Journal:  J Rheumatol       Date:  2009-10-15       Impact factor: 4.666

7.  The widening mortality gap between rheumatoid arthritis patients and the general population.

Authors:  Angel Gonzalez; Hilal Maradit Kremers; Cynthia S Crowson; Paulo J Nicola; John M Davis; Terry M Therneau; Veronique L Roger; Sherine E Gabriel
Journal:  Arthritis Rheum       Date:  2007-11

8.  Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients?

Authors:  A Gonzalez; H Maradit Kremers; C S Crowson; K V Ballman; V L Roger; S J Jacobsen; W M O'Fallon; S E Gabriel
Journal:  Ann Rheum Dis       Date:  2007-05-21       Impact factor: 19.103

9.  The Framingham predictive instrument in chronic kidney disease.

Authors:  Daniel E Weiner; Hocine Tighiouart; Essam F Elsayed; John L Griffith; Deeb N Salem; Andrew S Levey; Mark J Sarnak
Journal:  J Am Coll Cardiol       Date:  2007-07-02       Impact factor: 24.094

10.  Evaluating the performance of the Framingham risk equations in a population with diabetes.

Authors:  P McEwan; J E Williams; J D Griffiths; A Bagust; J R Peters; P Hopkinson; C J Currie
Journal:  Diabet Med       Date:  2004-04       Impact factor: 4.359

View more
  22 in total

1.  Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti-tumor necrosis factor therapy.

Authors:  Jeffrey R Curtis; Ani John; Onur Baser
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-09       Impact factor: 4.794

2.  [The safety of biologics : a risk-benefit assessment of treating rheumatoid arthritis with biologics based on registry data on mortality].

Authors:  O Sander
Journal:  Z Rheumatol       Date:  2010-11       Impact factor: 1.372

Review 3.  Selection bias in rheumatic disease research.

Authors:  Hyon K Choi; Uyen-Sa Nguyen; Jingbo Niu; Goodarz Danaei; Yuqing Zhang
Journal:  Nat Rev Rheumatol       Date:  2014-04-01       Impact factor: 20.543

Review 4.  New insights into the functional role of the rheumatoid arthritis shared epitope.

Authors:  Denise E de Almeida; Song Ling; Joseph Holoshitz
Journal:  FEBS Lett       Date:  2011-03-22       Impact factor: 4.124

5.  Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center.

Authors:  Douglas B Johnson; Debra L Friedman; Elizabeth Berry; Ilka Decker; Fei Ye; Shilin Zhao; Alicia K Morgans; Igor Puzanov; Jeffrey A Sosman; Christine M Lovly
Journal:  Cancer Immunol Res       Date:  2015-02-03       Impact factor: 11.151

Review 6.  New treatments for inflammatory rheumatic disease.

Authors:  Carlo Selmi; Elena Generali; Marco Massarotti; Gerolamo Bianchi; Carlo A Sciré
Journal:  Immunol Res       Date:  2014-12       Impact factor: 2.829

7.  Absence of β2 integrins impairs regulatory T cells and exacerbates CD4+ T cell-dependent autoimmune carditis.

Authors:  Stefanie Haasken; Jennifer L Auger; Bryce A Binstadt
Journal:  J Immunol       Date:  2011-07-27       Impact factor: 5.422

8.  Artesunate Ameliorates Functional Limitations in Freund's Complete Adjuvant-Induced Monoarthritis in Rat by Maintaining Oxidative Homeostasis and Inhibiting COX-2 Expression.

Authors:  B Guruprasad; Priyanka Chaudhary; Tenzin Choedon; Vijay L Kumar
Journal:  Inflammation       Date:  2015       Impact factor: 4.092

9.  Looking through the 'window of opportunity': is there a new paradigm of podiatry care on the horizon in early rheumatoid arthritis?

Authors:  James Woodburn; Kym Hennessy; Martijn Pm Steultjens; Iain B McInnes; Deborah E Turner
Journal:  J Foot Ankle Res       Date:  2010-05-17       Impact factor: 2.303

Review 10.  Potential benefits of green tea polyphenol EGCG in the prevention and treatment of vascular inflammation in rheumatoid arthritis.

Authors:  Sharayah Riegsecker; Dustin Wiczynski; Mariana J Kaplan; Salahuddin Ahmed
Journal:  Life Sci       Date:  2013-07-19       Impact factor: 5.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.